Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors
The rapid global spread of the SARS-CoV-2 virus facilitated the development of novel direct-acting antiviral agents (DAAs). The papain-like protease (PLpro) has been proposed as one of the major SARS-CoV-2 targets for DAAs due to its dual role in processing viral proteins and facilitating the host's immune suppression. This dual role makes identifying small molecules that can effectively neutralize SARS-CoV-2 PLpro activity a high-priority task. However, PLpro drug discovery faces a significant challenge due to the high mobility and induced-fit effects in the protease's active site. Herein, we virtually screened the ZINC20 database with Deep Docking (DD) to identify prospective noncovalent PLpro binders and combined ultra-large consensus docking with two pharmacophore (ph4)-filtering strategies. The analysis of active compounds revealed their somewhat-limited diversity, likely attributed to the induced-fit nature of PLpro's active site in the crystal structures, and therefore, the use of rigid docking protocols poses inherited limitations. The top hits were assessed against recombinant viral proteins and live viruses, demonstrating desirable inhibitory activities. The best compound VPC-300195 (IC50: 15 μM) ranks among the top noncovalent PLpro inhibitors discovered through in silico methodologies. In the search for novel SARS-CoV-2 PLpro-specific chemotypes, the identified inhibitors could serve as diverse templates for the development of effective noncovalent PLpro inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Journal of chemical information and modeling - 63(2023), 7 vom: 10. Apr., Seite 2158-2169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garland, Olivia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.04.2023 Date Revised 05.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.jcim.2c01641 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354362046 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354362046 | ||
| 003 | DE-627 | ||
| 005 | 20231226062044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jcim.2c01641 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354362046 | ||
| 035 | |a (NLM)36930801 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garland, Olivia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2023 | ||
| 500 | |a Date Revised 05.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The rapid global spread of the SARS-CoV-2 virus facilitated the development of novel direct-acting antiviral agents (DAAs). The papain-like protease (PLpro) has been proposed as one of the major SARS-CoV-2 targets for DAAs due to its dual role in processing viral proteins and facilitating the host's immune suppression. This dual role makes identifying small molecules that can effectively neutralize SARS-CoV-2 PLpro activity a high-priority task. However, PLpro drug discovery faces a significant challenge due to the high mobility and induced-fit effects in the protease's active site. Herein, we virtually screened the ZINC20 database with Deep Docking (DD) to identify prospective noncovalent PLpro binders and combined ultra-large consensus docking with two pharmacophore (ph4)-filtering strategies. The analysis of active compounds revealed their somewhat-limited diversity, likely attributed to the induced-fit nature of PLpro's active site in the crystal structures, and therefore, the use of rigid docking protocols poses inherited limitations. The top hits were assessed against recombinant viral proteins and live viruses, demonstrating desirable inhibitory activities. The best compound VPC-300195 (IC50: 15 μM) ranks among the top noncovalent PLpro inhibitors discovered through in silico methodologies. In the search for novel SARS-CoV-2 PLpro-specific chemotypes, the identified inhibitors could serve as diverse templates for the development of effective noncovalent PLpro inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a papain-like protease, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a EC 3.4.22.2 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 650 | 7 | |a Peptide Hydrolases |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 700 | 1 | |a Ton, Anh-Tien |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi, Shoeib |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Jason R |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacic, Suzana |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Kurtis |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Mohit |e verfasserin |4 aut | |
| 700 | 1 | |a Ban, Fuqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jaeyong |e verfasserin |4 aut | |
| 700 | 1 | |a Vuckovic, Marija |e verfasserin |4 aut | |
| 700 | 1 | |a Worrall, Liam J |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Robert N |e verfasserin |4 aut | |
| 700 | 1 | |a Pantophlet, Ralph |e verfasserin |4 aut | |
| 700 | 1 | |a Strynadka, Natalie C J |e verfasserin |4 aut | |
| 700 | 1 | |a Cherkasov, Artem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of chemical information and modeling |d 2005 |g 63(2023), 7 vom: 10. Apr., Seite 2158-2169 |w (DE-627)NLM153268735 |x 1549-960X |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:7 |g day:10 |g month:04 |g pages:2158-2169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jcim.2c01641 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 7 |b 10 |c 04 |h 2158-2169 | ||